BackgroundTraumatic brain injury (TBI) is a major health problem worldwide. Secondary injuries after TBI, including diffuse axonal injury (DAI) often occur, and proper treatments are needed in this regard. It has been shown that glibenclamide could reduce secondary brain damage after experimental TBI and improve outcomes.ObjectivesWe aim to evaluate the role of glibenclamide on the short-term outcome of patients with DAI due to moderate to severe TBI.Patients and MethodsIn this controlled randomized clinical trial, 40 patients with moderate to severe TBI were assigned to glibenclamide (n = 20) and control (n = 20) groups. Six hours after admission the intervention group received 1.25 mg glibenclamide every 12 hours. The Glasgow coma scale (GCS) was administered at admission, in the first 24 and 48 hours, at one week post-trauma and at discharge. The Glasgow outcome scale (GOS) was also administered at discharge. All results were evaluated and compared between groups.ResultsPatients treated with glibenclamide compared to the control group had a significantly better GCS score one week post-trauma (P = 0.003) and at discharge (P = 0.004), as well as a better GOS score at discharge (P = 0.001). The glibenclamide group also had a shorter length of hospital stay compared to the control group (P = 0.03). In the control group, two patients (10%) died during the first week post-trauma, but there was no mortality in the glibenclamide group (P = 0.48).ConclusionsTreatment with glibenclamide in patients with DAI due to moderate to severe TBI significantly improves short-term outcomes.
Current treatment of chronic wounds
has been critically limited
by various factors, including bacterial infection, biofilm formation,
impaired angiogenesis, and prolonged inflammation. Addressing these
challenges, we developed a multifunctional wound dressing-based three-pronged
approach for accelerating wound healing. The multifunctional wound
dressing, composed of nanofibers, functional nanoparticles, natural
biopolymers, and selected protein and peptide, can target multiple
endogenous repair mechanisms and represents a promising alternative
to current wound healing products.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.